XML 63 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
 6 Months Ended
Jul. 02, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The below tables show select financial measures by reporting segment (in millions):
 
 
July 2,
2016
 
December 31, 2015
Total Assets
 
Restated
 
Restated
CHC
 
$
3,748.3

 
$
3,384.8

BCH
 
6,290.7

 
7,083.5

Rx
 
3,340.1

 
2,738.0

Specialty Sciences
 
4,710.1

 
5,930.2

Other
 
202.0

 
213.1

Total
 
$
18,291.2

 
$
19,349.6

 
Three Months Ended
 
July 2, 2016
 
June 27, 2015
 
Restated
 
Restated
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
686.3

 
$
115.0

 
$
19.0

 
$
746.4

 
$
130.1

 
$
16.6

BCH
343.1

 
(1.8
)
 
39.5

 
368.3

 
16.7

 
34.2

Rx
293.3

 
96.8

 
29.9

 
278.3

 
99.5

 
18.6

Specialty Sciences
—

 
(3.8
)
 
—

 
—

 
(5.2
)
 
0.2

Other
17.8

 
(1.3
)
 
0.5

 
22.2

 
1.9

 
0.5

Unallocated
—

 
(20.1
)
 
—

 
—

 
(50.7
)
 
—

Total
$
1,340.5

 
$
184.8

 
$
88.9

 
$
1,415.2

 
$
192.3

 
$
70.1



 
Six Months Ended
 
July 2, 2016
 
June 27, 2015
 
Restated
 
Restated
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
 
Total Revenue
 
Operating Income (Loss)
 
Intangible Asset Amortization
CHC
$
1,386.6

 
$
214.5

 
$
38.8

 
$
1,431.3

 
$
234.4

 
$
32.8

BCH*
705.9

 
(400.0
)
 
74.9

 
368.3

 
16.8

 
34.2

Rx
556.9

 
191.1

 
59.4

 
529.9

 
199.5

 
36.9

Specialty Sciences
—

 
(5.1
)
 
—

 
—

 
(8.5
)
 
0.5

Other
38.4

 
4.1

 
1.0

 
52.9

 
12.4

 
0.9

Unallocated
—

 
(51.4
)
 
—

 
—

 
(71.9
)
 
—

Total*
$
2,687.8

 
$
(46.8
)
 
$
174.1

 
$
2,382.4

 
$
382.7

 
$
105.3


*
The BCH segment was created on March 30, 2015 as a result of the Omega acquisition, thus data for the six months ended June 27, 2015 includes only three months of results from operations attributable to Omega.

The Specialty Sciences segment recognized expense (income) of $910.8 million and $69.2 million for the three months ended July 2, 2016 and June 27, 2015, respectively, and $1.1 billion and $(31.5) million for the six months ended July 2, 2016 and June 27, 2015, respectively, for the change in the fair value of the Tysabri® royalty stream during each period.